Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting

SAN DIEGO–(BUSINESS WIRE)– #ASCO23–Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks